Evidence map›Paper›PMID 28673287›Full record

ArticleMalaria journal2017

New gorilla adenovirus vaccine vectors induce potent immune responses and protection in a mouse malaria model.

Keith Limbach, Maureen Stefaniak, Ping Chen, Noelle B Patterson, Grant Liao, Shaojie Weng, Svetlana Krepkiy, Greg Ekberg, Holly Torano, Damodar Ettyreddy and 12 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Malaria journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 17 citations in OpenAlex.

  1. Developing the next-generation of adenoviral vector vaccines.Human vaccines & immunotherapeutics · 2025
    Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Combination Therapies for HPV-Associated Malignancies.Journal of clinical & cellular immunology · 2021
    Article
  8. Advances in Alpha-1 Antitrypsin Gene Therapy.American journal of respiratory cell and molecular biology · 2020
    Review
  9. Non-Human Primate-Derived Adenoviruses for Future Use as Oncolytic Agents?International journal of molecular sciences · 2020
    Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Profiling the Targets of Protective CD8Molecular therapy. Methods & clinical development · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 5 institutions in 2 countries.

Keith LimbachMalaria Department, Naval Medical Research Center, 503 Robert Grant Avenue, Silver Spring, MD, USA.
Maureen StefaniakMalaria Department, Naval Medical Research Center, 503 Robert Grant Avenue, Silver Spring, MD, USA.
Ping ChenGenVec Incorporated, 910 Clopper Road, Suite 220N, Gaithersburg, MD, USA.
Noelle B PattersonMalaria Department, Naval Medical Research Center, 503 Robert Grant Avenue, Silver Spring, MD, USA.
Grant LiaoGenVec Incorporated, 910 Clopper Road, Suite 220N, Gaithersburg, MD, USA.
Shaojie WengGenVec Incorporated, 910 Clopper Road, Suite 220N, Gaithersburg, MD, USA.
Svetlana KrepkiyGenVec Incorporated, 910 Clopper Road, Suite 220N, Gaithersburg, MD, USA.
Greg EkbergGenVec Incorporated, 910 Clopper Road, Suite 220N, Gaithersburg, MD, USA.
Holly ToranoGenVec Incorporated, 910 Clopper Road, Suite 220N, Gaithersburg, MD, USA.
Damodar EttyreddyGenVec Incorporated, 910 Clopper Road, Suite 220N, Gaithersburg, MD, USA.
Kalpana GowdaMalaria Department, Naval Medical Research Center, 503 Robert Grant Avenue, Silver Spring, MD, USA.
Sharvari SonawaneMalaria Department, Naval Medical Research Center, 503 Robert Grant Avenue, Silver Spring, MD, USA.
Arnel BelmonteMalaria Department, Naval Medical Research Center, 503 Robert Grant Avenue, Silver Spring, MD, USA.
Esteban AbotMalaria Department, Naval Medical Research Center, 503 Robert Grant Avenue, Silver Spring, MD, USA.
Martha SedegahMalaria Department, Naval Medical Research Center, 503 Robert Grant Avenue, Silver Spring, MD, USA.
Michael R HollingdaleMalaria Department, Naval Medical Research Center, 503 Robert Grant Avenue, Silver Spring, MD, USA.
Ann MoormannUniversity of Massachusetts Medical School, Worcester, MA, USA.
John VululeCenter for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya.
Eileen VillasanteMalaria Department, Naval Medical Research Center, 503 Robert Grant Avenue, Silver Spring, MD, USA.
Thomas L RichieMalaria Department, Naval Medical Research Center, 503 Robert Grant Avenue, Silver Spring, MD, USA.
Douglas E BroughGenVec Incorporated, 910 Clopper Road, Suite 220N, Gaithersburg, MD, USA.
Joseph T BruderGenVec Incorporated, 910 Clopper Road, Suite 220N, Gaithersburg, MD, USA. joetbruder@gmail.com.
GenVec · USNaval Medical Research Command · USHenry M. Jackson Foundation · USKenya Medical Research Institute · KEUniversity of Massachusetts Chan Medical School · US

Funding

Immunologic Studies of Endemic Burkitt's LymphomaK08AI051565 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI MOORMANN, ANN M · 2002 to 2006
$542k
NIAID NIH HHS K08 AI051565
6 · The paper itself

Abstract

backgroundA DNA-human Ad5 (HuAd5) prime-boost malaria vaccine has been shown to protect volunteers against a controlled human malaria infection. The potency of this vaccine, however, appeared to be affected by the presence of pre-existing immunity against the HuAd5 vector. Since HuAd5 seroprevalence is very high in malaria-endemic areas of the world, HuAd5 may not be the most appropriate malaria vaccine vector. This report describes the evaluation of the seroprevalence, immunogenicity and efficacy of three newly identified gorilla adenoviruses, GC44, GC45 and GC46, as potential malaria vaccine vectors.

resultsThe seroprevalence of GC44, GC45 and GC46 is very low, and the three vectors are not efficiently neutralized by human sera from Kenya and Ghana, two countries where malaria is endemic. In mice, a single administration of GC44, GC45 and GC46 vectors expressing a murine malaria gene, Plasmodium yoelii circumsporozoite protein (PyCSP), induced robust PyCSP-specific T cell and antibody responses that were at least as high as a comparable HuAd5-PyCSP vector. Efficacy studies in a murine malaria model indicated that a prime-boost regimen with DNA-PyCSP and GC-PyCSP vectors can protect mice against a malaria challenge. Moreover, these studies indicated that a DNA-GC46-PyCSP vaccine regimen was significantly more efficacious than a DNA-HuAd5-PyCSP regimen.

conclusionThese data suggest that these gorilla-based adenovectors have key performance characteristics for an effective malaria vaccine. The superior performance of GC46 over HuAd5 highlights its potential for clinical development.

Indexed as

Adenoviruses, SimianAdenovirus Infections, HumanAnimalsAntibodies, ViralDisease Models, AnimalFemaleGenetic VectorsGhanaGorilla gorillaHumansInterferon-gammaKenyaMalariaMalaria VaccinesMiceMice, Inbred BALB CAntibodies, Viralcircumsporozoite protein, ProtozoanInterferon-gammaMalaria VaccinesProtozoan ProteinsAdenovectorAdenovirusEfficacyGeneticGorillaMalariaMolecularNon-human primateSingle-administrationVaccine

Identifiers

PMID28673287
PMCPMC5496260
OpenAlexW2731616574

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.